| Number | Pathways | DEGs | value | Genes |
| 1 | Primary immunodeficiency signaling | 4 | 0.000120085 | ADA, CD79A, IGHD, IGLL1/IGLL5 | 2 | Altered T-cell and B-cell signaling in rheumatoid arthritis | 4 | 0.000772903 | CD28, SLAMF1, TGFB1, CD79A | 3 | T-helper cell differentiation | 3 | 0.004440048 | CD28, TGFB1, TNFRSF11B | 4 | Cyclins and cell cycle regulation | 3 | 0.006251755 | TGFB1, CDK7, E2F5 | 5 | B-cell development | 2 | 0.010284999 | CD79A, IGHD | 6 | Leukocyte extravasation signaling | 4 | 0.013183985 | CXCR4, CD44, MLLT4, MMP12 | 7 | Atherosclerosis signaling | 3 | 0.019146088 | TGFB1, CXCR4, PLA2G10 | 8 | Arachidonic acid metabolism | 3 | 0.021798453 | GPX3, PLA2G10, CYP4F3 | 9 | Colorectal cancer metastasis signaling | 4 | 0.027547337 | RHOQ, TGFB1, PTGER2, MMP12 | 10 | Aryl hydrocarbon receptor signaling | 3 | 0.028201448 | TGFB1, NFIA, GSTA5 | 11 | Hepatic fibrosis/hepatic stellate cell activation | 3 | 0.029806364 | TGFB1, EDNRA, TNFRSF11B | 12 | Glioma invasiveness signaling | 2 | 0.030646264 | RHOQ, CD44 | 13 | Glutathione metabolism | 2 | 0.031643803 | GPX3, GSTA5 | 14 | Cell cycle: G1/S checkpoint regulation | 2 | 0.03367696 | TGFB1, E2F5 | 15 | Eicosanoid signaling | 2 | 0.03367696 | PLA2G10, PTGER2 | 16 | Induction of apoptosis by HIV1 | 2 | 0.03367696 | CXCR4, TNFRSF11B | 17 | Hypoxia signaling in the cardiovascular system | 2 | 0.037891658 | UBE2D2, HIF1AN | 18 | Tight junction signaling | 3 | 0.038540606 | TGFB1, MLLT4, TNFRSF11B | 19 | Germ cell-sertoli cell junction signaling | 3 | 0.039164578 | RHOQ, TGFB1, MLLT4 | 20 | Mitotic roles of Polo-like kinase | 2 | 0.040070987 | TGFB1, PTTG1 | 21 | Purine metabolism | 4 | 0.043235613 | ENTPD4, ABCC1, ADA, SEPT1 | 22 | Endothelin-1 signaling | 3 | 0.046366635 | PLA2G10, EDNRA, PTGER2 | 23 | Regulation of IL-2 expression in activated and anergic T Lymphocytes | 2 | 0.05532422 | CD28, TGFB1 | 24 | Chronic myeloid leukemia signaling | 2 | 0.073630475 | TGFB1, E2F5 | 25 | HMGB1 signaling | 2 | 0.075004378 | RHOQ, TNFRSF11B |
|
|